Treatment continuation rate in relation to efficacy and toxicity in long-term therapy with low-dose methotrexate, sulfasalazine, and bucillamine in 1358 Japanese patients with rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 24, Issue 3, 2006, Pages 260-267

  Nagashima, Masakazu ^a   Matsuoka, T ^a   Saitoh, K ^a   Koyama, T ^a   Kikuchi, O ^a   Yoshino, S ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Adverse drug reaction; Bucillamine; Continuation rate; Kaplan Meier method; Methotrexate; Rheumatoid arthritis; Sulfasalazine

Indexed keywords

AURANOFIN; AUROTHIOMALATE; BUCILLAMINE; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FOLIC ACID; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE;

ADOLESCENT; ADULT; AGED; ARTHRALGIA; ARTHRITIS; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; INCIDENCE; JAPAN; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LONG TERM CARE; LOW DRUG DOSE; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORNING STIFFNESS; NAUSEA; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN ANALYSIS; RHEUMATOID ARTHRITIS; SKIN TOXICITY; TREATMENT DURATION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CYSTEINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; JOINTS; MALE; METHOTREXATE; MIDDLE AGED; PAIN; PREDNISOLONE; SULFASALAZINE; TREATMENT OUTCOME;

EID: 33746617230     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. PINCUS T, MARCUM SB, CALLAHAN LF: Long term drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol 1992; 19: 1885-94.
2. KREMER JM: Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: follow-up after a mean of 13.3 years. Arthritis Rheum 1997; 40: 984-5.
3. WEINBLATT ME, WEISSMAN BN, HOLDSWORTH DE et al.: Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. Arthritis Rheum 1992; 35: 129-37.
4. BOLOGNA C, SANY JJ: Methotrexate as the initial second-line disease modifying agent in the treatment of rheumatoid arthritis patients. Clin Exp Rheum 1997; 15: 597-601.
5. CAPELL HA, MAIDEN N, MADHOK R, HAMPSON R, THOMSON EA: Intention-to-treat analysis of 200 patients with rheumatoid arthritis 12 years after random allocation to either sulfasalazine or penicillamine. J Rheumatol 1998; 25: 1880-6.
6. JONES E, JONES JV, WOODBURY JFL: Response to sulfasalazine in rheumatoid arthritis: Life table analysis of a 5-year follow up. J Rheumatol 1991; 18: 195-8.
7. ICHIKAWA Y, SHINOZAWA T, YOSHIDA T et al.: Methotrexate and salazosulphapyridine in the long term treatment of rheumatoid arthritis. Ryumachi 1995; 35: 663-70.
8. WOLFE F, HAWLEY DJ, CATHEY MA: Termination of slow acting anti-rheumatic therapy in rheumatoid arthritis: A 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990; 17: 994-1002.
9. SUAREZ-ALMAZOR ME, SOSKOLNE CL, SAUNDERS D, RUSSELL AS: Use of second line drugs for the treatment of rheumatoid arthritis in Edmonton, Alberta. Patterns of prescription and long term effectiveness. J Rheumatol 1995; 22: 836-43.
10. GALINDO-RODRIGUEZ G, AVINA-ZUBIETA JA, RUSSELL AS, SUAREZ-ALMAZOR ME: Disappointing long term results with disease modifying antirheumatic drugs. A practice based study. J Rheumatol 1999; 26: 2337-43.
11. MAETZEL A, WONG A, STRAND V, TUGWELL P, WELLS G, BOMBARDIER C: Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology 2000; 39: 975-81.
12. ALETAHA D, SMOLEN JS: The rheumatoid arthritis patient in the clinic: comparing more than 1300 consecutive DMARD courses. Rheumatology 2002; 41: 1367-74.
13. MAINI R, ST CLAIR EW, BREEDVELD F et al.: Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-9.
14. SMOLEN JS, KALDEN JR, SCOTT DL et al.: Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomized, multicentre trial. European Leflunomide Study Group. Lancet 1999; 353: 259-66.
15. WEINBLATT ME, KREMER JM, BANKHURST AD et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-9.
16. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
17. FRIES JF: Reevaluating the therapeutic approach to rheumatoid arthritis: the "saw-tooth" strategy. J Rheumatol 1990; 17: 12-5.
18. KASHIWAZAKI S, ICHIKAWA Y, SUGAWARA S et al.: Determination of the clinical optimal dose of L-377 (methotrexate capsule) for the treatment of rheumatoid arthritis. Jap J Inflammation 1996; 16: 437-58.
19. PINCUS T, YAZICI Y, SOKKA T, ALETAHA D, SMOLEN JS: Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis. Clin Exp Rheum 2003; 21 (Suppl. 31): S179-85.
20. KREMER JM, PHELPS CT: Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months. Arthritis Rheum 1992; 35: 138-45.
21. ALARCON GS, TRACY IC, BLACKBURN WDJR: Methotrexate in rheumatoid arthritis: toxic effects as the major factor in limiting long term treatment. Arthritis Rheum 1989; 32: 671-6.
22. HOEKSTRA M, VAN DE LAAR MA, BERNELOT MOENS HJ, KRUIJSEN MW, HAAGSMA CJ: Long term observational study of methotrexate use in a Dutch cohort of 1022 patients with rheumatoid arthritis. J Rheumatol 2003; 30: 2325-9.
23. CARROLL GJ, WILL RK, BREIDAHL PD, TINSLEY LM: Sulphasalazine versus penicillamine in the treatment of rheumatoid arthritis. Rheumatol Int 1989; 8: 251-5.
24. SITUNAYAKE RD, GRINDULIS KA, McCONKEY B: Long term treatment of rheumatoid arthritis with sulphasalazine, gold or penicillamine: a comparison using life-table methods. Ann Rheum Dis 1987; 46: 177-83.
25. McENTEGART A, PORTER D, CAPELL HA, THOMSON EA: Sulphasalazine has a better efficacy/toxicity profile than auranofin- evidence from a 5 year prospective, randomized trial. J Rheumatol 1996; 23: 1887-90.
26. ALETAHA D, SMOLEN JS: Effectiveness profiles and dose dependent retention of traditional disease modifying anti rheumatic drugs for rheumatoid arthritis an observational study. J Rheumatol 2002; 29: 1631-8.
27. CHOI HK, HERNAN MA, SEEGER JD, ROBINS JM, WOLFE F: Methotrexate and mortality in patients with rheumatoid arthritis:A prospective study. Lancet 2002; 359: 1173-7.
28. De La MATA J, BLANCO FJ, GOMEZ-REINO JJ: Survival analysis of disease modifying antirhumatic drugs in Spanish rheumatoid arthritis patients. Ann Rheum Dis 1995; 54: 881-5.
29. PAPADOPOULOS NG, ALAMANOS Y, PAPADOPOULOS IA, TSIFETAKI N, VOULGARI PV, DROSOS AA: Disease modifying antirheumatic drugs in early rheumatoid arthritis: A longterm observational study. J Rheum 2002; 29: 261-6.
30. NAGASHIMA M, SHU G, YAMAMOTO K, YAMAHATSU S, YOSHINO S: The ability of disease-modifying antirheumatic drugs to induce and maintain improvement in patients with rheumatoid arthritis -Epidemiology of DMARD treatment in Japan. Clin Exp Rheum 2005; 23: 27-35.
31. PAULUS HE: The use of combinations of disease modifying antirheumatic agents in rheumatoid arthritis. Arthritis Rheum 1990; 33: 113-20.
32. AXTENS RS, MORAND EF, LITTLEJOHN GO: Combination therapy with methotrexate and sulphasalazine in rheumatoid arthritis -tolerance of therapy. Ann Rheum Dis 1994; 53: 703.
33. LANDEWE RB, BOERS M, VERHOEVEN AC et al.: COBRA combination therapy in patients with early rheumatoid arthritis. Arthritis Rheum 2002; 46: 347-56.
34. MAILLEFERT JF, COMBE B, GOUPILLE P, CANTAGREL A, DOUGADOS M: Long term structural effects of combination therapy in patients with early rheumatoid arthritis: five year follow up of a prospective double blind controlled study. Ann Rheum Dis 2003; 62: 764-6.
35. WILLKENS RF, SHARP JT, STABLEIN D, MARKS C, WORTMANN R: Comparison of azathioprine methotrexate, and the combination of the two in the treatment of rheumatoid arthritis. A forty-eight-week controlled clinical trial with radiologic outcome assessment. Arthritis Rheum 1995; 38: 1799-806.
36. RAU R, SCHLEUSSER B, HERBORN G, KARGER T: Long term combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy. J Rheumatol 1998; 25: 1485-92.
37. MULHERIN D, FITGERALD O, BRESNIHAN B: Clinical improvement and radiological deterioration in rheumatoid arthritis: Evidence that pathogenesis of synovial inflammation and articular erosion may differ. Br J Rheumatol 1996; 35: 1263-8.
38. FEX E, JOHNSON K, JOHNSON U, EBERHARDT K: development of radiographic damage during the first 5-6 yr of rheumatoid arthritis. A prospective follow-up study of a Swedish cohort. Br J Rheumatol 1996; 35: 1106-15.
39. CALLAHAN LF, PINCUS T, HUSTON JW, III, BROOKS RH, NANCE EP JR, KAYE JJ: Measures of activity and damage in rheumatoid arthritis: Depiction of changes and prediction of mortality over five years. Arthritis Care Res 1997; 10: 381-94.
40. PINCUS T, SOKKA T: Partial control of Core Data Set measures and Disease Activity Score (DAS) measures of inflammation dose not prevent long-term damage: evidence from longitudinal observation over 5-20 years. Clin Exp Rheumatol 2002; 20 (Suppl. 27): S42-48.
41. PINCUS T, SOKKA T: Quantitative measures and indices to assess rheumatoid arthritis in clinical trials and clinical care. Rheum Dis Clin North Am 2004; 30: 725-51.